Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
6.41
Nov 16 • 3:55 PM ET Dollar change-1.10 Percentage change(-14.58%)
Nov 12, 4:21 PMAtrium Therapeutics doses first patient in Phase 1/2 ATR 1072 trial for PRKAG2 syndrome
Index
-
Market Cap
138.38M
Enterprise Value
-93.33M
Income
-70.22M
Sales
38.82M
Book/sh
12.50
Cash/sh
10.77
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
-
IPO
Jun 12, 2020
P/E
-
Forward P/E
-
PEG
-
P/S
3.56
P/B
0.51
P/C
0.60
P/FCF
-
EV/EBITDA
-
EV/Sales
-2.40
Quick Ratio
10.46
Current Ratio
10.46
Debt/Eq
0.00
LT Debt/Eq
0.00
Option/Short
No / Yes
EPS (ttm)
-4.12
EPS next Y
-5.36
EPS next Q
-1.00
EPS this Y
26.46%
EPS next Y
-62.79%
EPS next 5Y
-7.45%
EPS past 3/5Y
-178.43% -
Sales past 3/5Y
38.09% -
EPS Y/Y TTM
-
Sales Y/Y TTM
-
EPS Q/Q
65.45%
Sales Q/Q
298.26%
Insider Own
2.96%
Insider Trans
0.00%
Inst Own
62.43%
Inst Trans
-4.70%
ROA
-
ROE
-
ROIC
-34.25%
Gross Margin
97.51%
Oper. Margin
-194.82%
Profit Margin
-180.89%
SMA20
-20.92%
SMA50
-24.48%
SMA200
-45.79%
Trades
Shs Outstand
22.28M
Shs Float
20.93M
52W High
16.77 -61.75%
52W Low
7.47 -14.12%
Volatility
4.22% 4.63%
ATR (14)
0.46
RSI (14)
22.26
Beta
-
Rel Volume
1.04
Avg Volume
289.63K
Volume
299,380
Perf Week
-23.45%
Perf Month
-16.36%
Perf Quarter
-50.04%
Perf Half Y
-50.46%
Perf YTD
-56.00%
Perf Year
-
Perf 3Y
-
Perf 5Y
-
Perf 10Y
-
Prev Close
7.51
Price
6.41
Change %
-14.58%
Consensus
Strong Buy
Avg. Price Target
$22.00
Implied Upside
+242.9%
Analysts16incl. previous ratings
Rating Distribution16 Buy · 0 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Oct 22, 2026Initiated
RRoth Capital
Buy$15+133.8%
Aug 06, 2026Initiated
HH.C. Wainwright
Buy$25+289.7%
Jun 18, 2026Initiated
CCantor Fitzgerald
Overweight$25+289.7%
May 15, 2026Initiated
LLeerink Partners
Outperform$25+289.7%
Mar 11, 2026Initiated
WFC logoWWells Fargo
Overweight$25+289.7%
Sep 17, 2025Initiated
RRoth Capital
Buy$62+866.5%
Jul 10, 2025Resumed
GS logoGGoldman
Buy$55+757.4%
Jun 24, 2025Initiated
BBernstein
Outperform$50+679.4%
Jun 17, 2025Initiated
WWolfe Research
Outperform$55+757.4%
Jun 11, 2025Initiated
RJF logoRRaymond James
Strong Buy$65+913.3%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Hughes Steven GeorgeChief Medical OfficerJan 21 '26Sale72.454,895354,64331,599Jan 23 05:34 PM
Boyce SarahPresident and CEOJan 21 '26Sale72.4514,3871,042,338269,007Jan 23 05:34 PM
Flanagan W. MichaelChief Scientific OfficerJan 21 '26Sale72.456,534473,38885,093Jan 23 05:33 PM
MacLean Michael FChief Financial OfficerJan 21 '26Sale72.454,542329,06859,290Jan 23 05:33 PM
LEVIN ARTHUR ADirectorJan 21 '26Sale72.451,758127,36716,562Jan 23 05:33 PM
McCarthy TeresaChief Human Resources OfficerJan 21 '26Sale72.452,929212,206113,938Jan 23 05:33 PM
Boyce SarahPresident and CEOJan 07 '26Sale72.238,576619,444283,394Jan 09 05:13 PM
Calderaro Charles IIIChief Technical OfficerJan 07 '26Sale72.233,727269,20149,797Jan 09 05:13 PM
McCarthy TeresaChief Human Resources OfficerJan 07 '26Sale72.231,965141,932116,867Jan 09 05:13 PM
Moriarty John BChief Legal OfficerJan 07 '26Sale72.232,374171,47474,557Jan 09 05:12 PM
MacLean Michael FChief Financial OfficerJan 07 '26Sale72.231,974142,58263,832Jan 09 05:12 PM
Hughes Steven GeorgeChief Medical OfficerJan 07 '26Sale72.232,373171,40236,494Jan 09 05:12 PM
Flanagan W. MichaelChief Scientific OfficerJan 07 '26Sale72.232,373171,40291,627Jan 09 05:12 PM
Atrium Therapeutics, Inc. operates as a biopharmaceutical company that provides RNA therapeutics services to the heart to transform the standard of care for people living with cardiomyopathies. Its products pipeline includes two lead development candidates: ATR 1072 for PRKAG2 syndrome and ATR 1086 for PLN cardiomyopathy, both conditions are severe, life-threatening, rare autosomal dominant progressive cardiomyopathies with no approved treatment options and high unmet need. The company was founded on September 30, 2025 and is headquartered in San Diego, CA.
PresidentMs. Kathleen P. Gallagher
Chief Financial OfficerMr. Brendan Winslow
Pharm.D.Dr. Husam Younis Ph.D.
Chief Corporate Affairs OfficerMs. Stephanie Kenney
M.D.Dr. Steven George Hughes M.B.A.